Publication
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugOsimertinibcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 T798Icivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28274957
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 L869R1 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID6173A 54-year-old female with heavily pre-treated estrogen and progesterone receptor positive, ERBB2 nonamplified lobular metastatic breast carcinoma harboring ERBB2 L869R mutation exhibited almost comple… (full text at CIViC) PMID 28274957 · Hanker et al., 2017 · Open in CIViC | civic |
| ERBB2 T798I3 | ||||||||
| Afatinib | Malignant Breast Neoplasm | Predictive | D | Does Not Support Resistance | 2 | submitted | EID6176Efficacy of afatinib at reducing phosphorylation of key proteins was evaluated by western blot. NR6 mouse fibroblast cells transduced to co-express ERBB2 L869R and T798I responded to afatinib treatmen… (full text at CIViC) PMID 28274957 · Hanker et al., 2017 · Open in CIViC | civic |
| Neratinib | Malignant Breast Neoplasm | Predictive | C | Supports Resistance | 3 | submitted | EID6175A 54-year-old female with estrogen and progesterone receptor positive, ERBB2 non-amplified lobular heavily pretreated metastatic breast carcinoma harboring ERBB2 L869R, a CDH1 truncating mutation, ERB… (full text at CIViC) PMID 28274957 · Hanker et al., 2017 · Open in CIViC | civic |
| Osimertinib | Malignant Breast Neoplasm | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID6174Efficacy of osimertinib and its metabolite, AZ5104, at reducing phosphorylation of key proteins was evaluated by western blot. Osimertinib failed to induce substantial reductions in phosphorylated ERB… (full text at CIViC) PMID 28274957 · Hanker et al., 2017 · Open in CIViC | civic |